☆ 4.7 Article

SARS-CoV-2 Infection, Vaccination and Risk of Death in People with An Oncological Disease in Northeast Italy

JOURNAL OF PERSONALIZED MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022

Massimo Vicentini et al.

Summary: This study evaluated the risk of SARS-CoV-2 reinfection based on vaccination status, predominant variant, and time after initial infection. The results showed that two doses of vaccine and prior infection could reduce the risk of reinfection, while natural immunity had low protection against the Omicron BA.1 variant. Combined vaccination and natural immunity were more effective in preventing reinfection than either alone.

EUROSURVEILLANCE (2023)

Add to Collection

Article Pharmacology & Pharmacy

COVID-19 vaccination effectiveness and safety in vulnerable populations: a meta-analysis of 33 observational studies

Hui-Jun Li et al.

Summary: This study systematically analyzed the safety and efficacy of the COVID-19 vaccine in vulnerable populations and found lower antibody levels in these populations with no significant difference in adverse events. Closer attention is recommended for patients with hematological cancers. Subjects who received the combined vaccine had higher antibody levels.

FRONTIERS IN PHARMACOLOGY (2023)

Add to Collection

Article Oncology

Vaccination against SARS-CoV-2 and risk of hospital admission and death among infected cancer patients: A population-based study in northern Italy

Michele Gobbato et al.

Summary: The study investigated the risks of hospital admission and death among cancer patients infected with SARS-CoV-2 according to their vaccination status. The findings showed that unvaccinated patients had significantly higher risks of hospital admission and death compared to vaccinated patients. The study emphasizes the importance of SARS-CoV-2 vaccines in reducing hospital admission and death risks for cancer patients.

CANCER EPIDEMIOLOGY (2023)

Add to Collection

Review Oncology

COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review

S. L. Shear et al.

Summary: Vaccination has become essential for solid tumour patients to protect against COVID-19. This systematic review identified common safety profiles of the COVID-19 vaccine in these patients. The most commonly reported side effects after vaccination were injection site pain and lymphadenopathy, and the most common systemic symptoms were fatigue, musculoskeletal symptoms, and headache.

CLINICAL ONCOLOGY (2023)

Add to Collection

Review Oncology

Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis

Andrea Becerril-Gaitan et al.

Summary: Patients with cancer have impaired immune response to COVID-19 vaccination compared with controls, with lower seroconversion rates and higher likelihood of SARS-CoV-2 infection.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Medicine, General & Internal

Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study

Massimo Fabiani et al.

Summary: This study suggests that vaccine effectiveness against SARS-CoV-2 infection significantly decreased from 82% at 3-4 weeks after the second dose to 33% at 27-30 weeks after the second dose during the epidemic phase when the delta variant was predominant. Similarly, vaccine effectiveness against severe COVID-19 also decreased, albeit to a lesser extent, from 96% to 80% during the same time intervals. High risk individuals, those aged >= 80 years, and those aged 60-79 years did not seem to be protected against infection at 27-30 weeks after the second dose of vaccine.

BMJ-BRITISH MEDICAL JOURNAL (2022)

Add to Collection

Article Pharmacology & Pharmacy

COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information

Davide Mauri et al.

Summary: Language barrier and e-guidance availability in the native language are the most important barriers in communicating with patients regarding COVID-19 vaccination. To address this issue, researchers have developed a summary guidance translated into 28 languages, reaching over 70% of the global population.

REVIEWS ON RECENT CLINICAL TRIALS (2022)

Add to Collection

Article Infectious Diseases

Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities- surveillance results from southern Sweden, July 2021 to January 2022

Fredrik Kahn et al.

Summary: We compared the risk of severe COVID-19 between the periods of 2021 and 2022 in Scania county, Sweden, when Delta and Omicron were the dominant virus variants. Adjusting for factors like sex, age, comorbidities, prior infection, and vaccination, we found that the risk of severe disease from Omicron was significantly lower among vaccinated cases. It was also lower among the unvaccinated population, but remained high (> 5%) for older individuals and middle-aged men with multiple comorbidities. Efforts to increase vaccination uptake should continue.

EUROSURVEILLANCE (2022)

Add to Collection

Article Oncology

Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

David J. Pinato et al.

Summary: During the omicron outbreak, COVID-19 outcomes in cancer patients in Europe improved compared to the prevaccination period and the alpha-delta waves. However, unvaccinated cancer patients remained highly susceptible to SARS-CoV-2. Therefore, our findings support universal vaccination of cancer patients as a protective measure against COVID-19 morbidity and mortality.

LANCET ONCOLOGY (2022)

Add to Collection

Article Environmental Sciences

Assessing COVID-19-Related Excess Mortality Using Multiple Approaches-Italy, 2020-2021

Emiliano Ceccarelli et al.

Summary: This study estimated the excess mortality of COVID-19 in Italy and compared the results of three estimation models. The results showed that model 1 and model 2 had consistent results, while model 3 differed. Model 1 was the most stable towards changes in the baseline years, and model 2 had a lower cross-validation RMSE.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

Add to Collection

Review Health Policy & Services

The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence

Chelsea Carle et al.

Summary: The early literature on susceptibility to SARS-CoV-2/COVID-19 for people with cancer is characterized by biases and limited data. To provide high-quality evidence for decision-making, studies should control for other potential modifiers of infection risk and perform stratified analyses.

JOURNAL OF CANCER POLICY (2022)

Add to Collection

Review Oncology

Cancer associates with risk and severe events ofCOVID-19: A systematic review and meta-analysis

Yehong Tian et al.

Summary: The study found that cancer patients may have a higher likelihood of contracting COVID-19, with a pooled prevalence of 2.3% overall and 3.2% in Hubei province. Cancer comorbidity is significantly associated with severe events and death in COVID-19 patients, highlighting the need for special measures for individuals with cancer.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

Sjoukje F. Oosting et al.

Summary: This study aimed to evaluate the immunogenicity and safety of the mRNA-1273 COVID-19 vaccine for patients with solid tumours receiving systemic cancer treatment. The majority of patients developed an adequate antibody response after two vaccinations, indicating the vaccine is safe in these patients. Some patients with an inadequate response may benefit from a third vaccination.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

David J. Pinato et al.

Summary: This article is a retrospective registry study involving a large number of authors and their collaborative research outcomes.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Cumulative COVID-19 incidence, mortality and prognosis in cancer survivors: A population-based study in Reggio Emilia, Northern Italy

Lucia Mangone et al.

Summary: Despite having higher incidence rate ratios of testing, positive test, and hospitalization and death, cancer survivors had the same probability of being infected, but were at higher risk of death once infected.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

P. Grivas et al.

Summary: This study analyzed clinical factors and laboratory measurements of cancer patients with COVID-19, finding that factors such as age, sex, comorbidities, cancer type, and laboratory results were associated with COVID-19 severity. Patients diagnosed early in the pandemic had worse outcomes, and specific anticancer therapies may increase 30-day all-cause mortality. More research is needed to confirm these findings and caution may be needed in using certain anticancer treatments.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Alfredo Addeo et al.

Summary: Among cancer patients, most (94%) achieved seroconversion after receiving two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response.

CANCER CELL (2021)

Add to Collection

Review Oncology

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis

Marco Tagliamento et al.

Summary: A systematic review and meta-analysis found that adult patients with solid or hematological malignancies and SARS-CoV-2 infection have a high probability of mortality, with lung cancer patients having a higher case fatality rate (CFR) and breast cancer patients having a lower CFR.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Add to Collection

Article Oncology

Prevalence, determinants, and outcomes of SARS-COV-2 infection among cancer patients. A population-based study in northern Italy

Diego Serraino et al.

Summary: A population-based study conducted in northeastern Italy found that cancer patients have a lower risk of SARS-CoV-2 infection, but they have a higher mortality rate if infected compared to cancer-free individuals. The study highlights the need to continue protecting cancer patients from COVID-19 infection.

CANCER MEDICINE (2021)

Add to Collection

Article Oncology

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Annika Fendler et al.

Summary: A cohort study evaluated 585 cancer patients following vaccination with BNT162b2 or AZD1222 vaccines, finding lower antibody responses in patients with hematological malignancies compared to those with solid tumors. Patients with hematological malignancies also had reduced neutralizing antibody responses compared to individuals without cancer. The study highlights the importance of managing cancer patients during the ongoing COVID-19 pandemic.

NATURE CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer et al.

LANCET (2020)

Add to Collection

Article Public, Environmental & Occupational Health

Survival of Hospitalized COVID-19 Patients in Northern Italy: A Population-Based Cohort Study by the ITA-COVID-19 Network

Eliana Ferroni et al.

CLINICAL EPIDEMIOLOGY (2020)

Add to Collection

Review Oncology

Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data

Vassilis G. Giannakoulis et al.

JCO GLOBAL ONCOLOGY (2020)

Add to Collection

Article Oncology

SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer

Massimo Rugge et al.

NATURE CANCER (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.